Wednesday, May 28, 2014

'Nanodaisies' deliver drug cocktail to cancer cells

'Nanodaisies' deliver drug cocktail to cancer cells

Early tests of the “nanodaisy” drug delivery technique show promise against a number of cancers. Credit: Ran Mo.

( —Biomedical engineering researchers have developed
daisy-shaped, nanoscale structures that are made predominantly of
anti-cancer drugs and are capable of introducing a "cocktail" of
multiple drugs into cancer cells. The researchers are all part the joint
biomedical engineering program at North Carolina State University and
the University of North Carolina at Chapel Hill.

"We found that this technique was much better than conventional drug-delivery techniques at inhibiting the growth of lung cancer tumors in mice," says Dr. Zhen Gu, senior author of the paper and an assistant professor in the joint biomedical engineering
program. "And based on in vitro tests in nine different cell lines, the
technique is also promising for use against leukemia, breast, prostate,
liver, ovarian and brain cancers."

To make the "nanodaisies," the researchers begin with a solution that
contains a polymer called polyethylene glycol (PEG). The PEG forms long
strands that have much shorter strands branching off to either side.
Researchers directly link the anti-cancer drug camptothecin (CPT) onto
the shorter strands and introduce the anti-cancer drug doxorubicin (Dox)
into the solution.

PEG is hydrophilic, meaning it likes water. CPT and Dox are
hydrophobic, meaning they don't like water. As a result, the CPT and Dox
cluster together in the solution, wrapping the PEG around themselves.
This results in a daisy-shaped drug cocktail, only 50 nanometers in
diameter, which can be injected into a cancer patient.

Once injected, the nanodaisies float through the bloodstream until they are absorbed by cancer cells.
In fact, one of the reasons the researchers chose to use PEG is because
it has chemical properties that prolong the life of the drugs in the

Once in a cancer
cell, the drugs are released. "Both drugs attack the cell's nucleus,
but via different mechanisms," says Dr. Wanyi Tai, lead author and a
former postdoctoral researcher in Gu's lab.

"Combined, the drugs are more effective than either drug
is by itself," Gu says. "We are very optimistic about this technique
and are hoping to begin pre-clinical testing in the near future."

The paper, "Folding Graft Copolymer with Pedant Drug Segment for
Co-Delivery of Anticancer Drugs," is published online in the journal Biomaterials.

No comments:

Post a Comment